Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Barrett, et al. v. Envision Healthcare Corporation, et al.
Case Number:
1:18-cv-01068
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
February 16, 2021
Monteverde Attys Net $5.8M In Deal Ending Envision Sale Suit
Monteverde & Associates attorneys won a $5.8 million fee award Tuesday for representation of stockholders in a $17.4 million settlement resolving claims that Envision Healthcare Corp. executives undervalued the company ahead of its $9.9 billion sale to private equity firm KKR & Co. LP.
-
April 13, 2020
Envision Investor Seeks Class Nod In $9.9B KKR Sale Suit
A stockholder sought class certification Monday in Delaware federal court for his securities claims that Envision Healthcare Corp. tamped down company value estimates ahead of an allegedly unfair $9.9 billion cash and debt sale to private equity firm KKR & Co. LP in 2018.
-
November 05, 2018
Monteverde To Lead Class Action Over $9.9B Envision Deal
Monteverde & Associates won a lead counsel appointment in the consolidation of two class actions in a Delaware federal court Monday over the $9.9 billion sale of Envision Healthcare Corp. to private equity firm KKR & Co. LP, in which shareholders claim executives took part in a flawed sales process that undervalued the company.